

Migraine

Detailed Overview- Acute Treatments

Pharmascroll

Table of Contents

1. Migraine Definition.....	7
2. Types of Migraine.....	9
a. Classification based on Symptoms and severity	10
i. Migraine without Aura	10
ii. Migraine with Aura.....	10
b. Classification based on frequency of Migraine attacks	12
i. Low Frequency Episodic Migraine	12
ii. High Frequency Episodic Migraine.....	12
iii. Chronic Migraine.....	12
3. Causes of Migraine.....	13
4. Profile of Migraine Patient.....	15
5. Symptoms of Migraine.....	16
6. Disease progression and impact on QoL.....	19
7. Disease Diagnosis.....	21
a. Disease diagnosis through symptoms.....	21
b. Disease diagnosis through medical tests.....	22
8. Disease Epidemiology.....	24
a. US Epidemiology.....	25
b. UK Epidemiology.....	26
c. Germany Epidemiology.....	27
d. Italy Epidemiology.....	28
e. France Epidemiology.....	29

f. Spain Epidemiology.....	30
g. Japan Epidemiology.....	31
9. Factors impacting a physician’s prescription decision.....	32
a. Efficacy.....	33
b. Tolerability and Safety.....	35
c. Monitoring Requirements.....	38
d. Pricing and Reimbursement.....	40
10. Disease Modifying Therapies for Migraine.....	41
a. Ubrogepant.....	41
i. About the Product.....	41
ii. Patent and Trial Details.....	42
iii. Impact of Ubrogepant.....	44
b. Lasmiditan.....	45
i. About the Product.....	45
ii. Patent and Trial Details.....	46
iii. Impact of Lasmiditan.....	48
c. Semprana.....	49
i. About the Product.....	49
ii. Patent and Trial Details.....	50
iii. Impact of Semprana.....	51
d. Relpax.....	52
i. About the Product.....	52
ii. Patent and Trial Details.....	53

- iii. Impact of Relpax.....54
 - e. Imitrex.....55
 - i. About the Product.....55
 - ii. Patent and Trial Details.....56
 - iii. Impact of Imitrex.....57
- 11. Drug Attribute Analysis.....58
 - a. Ubrogепant.....58
 - b. Lasmiditan.....60
 - c. Semprana.....62
 - d. Relpax.....64
 - e. Imitrex.....65
- 12. Other Pipeline Products.....66
 - a. Number of Pipeline Products phase wise.....67
 - b. Number of Companies having other pipeline products phase wise...68
- 13. Migraine Market Sizing.....69
 - a. Ubrogепant.....69
 - i. Value sales in Migraine indication.....69
 - ii. Patient numbers in Migraine indication.....69
 - iii. Value sales by key geographies/countries.....70
 - iv. Patient numbers by key geographies/countries.....70
 - b. Lasmiditan.....71
 - i. Value sales in Migraine indication.....71
 - ii. Patient numbers in Migraine indication.....71

- iii. Value sales by key geographies/countries.....72
 - iv. Patient numbers by key geographies/countries.....72
 - c. Semprana.....73
 - i. Value sales in Migraine indication.....73
 - ii. Patient numbers in Migraine indication.....73
 - iii. Value sales by key geographies/countries.....74
 - iv. Patient numbers by key geographies/countries.....74
 - d. Relpax.....75
 - i. Value sales in Migraine indication.....75
 - ii. Patient numbers in Migraine indication.....75
 - iii. Value sales by key geographies/countries.....76
 - iv. Patient numbers by key geographies/countries.....76
- 14. Market Sizing Country Wise.....77
 - a. Global.....77
 - i. Value sales by Brand.....77
 - ii. Patient numbers by Brand.....77
 - b. US.....78
 - i. Value sales by Brand.....78
 - ii. Patient numbers by Brand.....78
 - c. Germany.....79
 - i. Value sales by Brand.....79
 - ii. Patient numbers by Brand.....79
 - d. France.....80

i. Value sales by Brand.....	80
ii. Patient numbers by Brand.....	80
e. Italy.....	81
i. Value sales by Brand.....	81
ii. Patient numbers by Brand.....	81
f. Spain.....	82
i. Value sales by Brand.....	82
ii. Patient numbers by Brand.....	82
g. UK.....	83
i. Value sales by Brand.....	83
ii. Patient numbers by Brand.....	83
h. Canada.....	84
i. Value sales by Brand.....	84
ii. Patient numbers by Brand.....	84
i. Australia.....	85
i. Value sales by Brand.....	85
ii. Patient numbers by Brand.....	85